Aprotinin does not prolong the Sonoclot aprotinin-insensitive activated clotting time.
OBJECTIVE
To determine whether a new Sonoclot-based, aprotinin-insensitive activated clotting time (aiACT) assay yields stable results over a broad range of aprotinin concentrations.


METHODS
Prospective trial conducted on in vitro blood samples.


METHODS
Tertiary-care teaching medical center.


METHODS
19 healthy adult volunteers.


METHODS
Whole blood samples were collected from volunteers. Heparin (2 U/mL) and escalating concentrations of aprotinin of 160 to 500 kallikrein inhibitory units (KIU)/mL were added in vitro.


RESULTS
Celite ACT, kaolin ACT, and aiACT assays were completed. The aiACT showed stable activated clotting time (ACT) results on heparinized, noncitrated blood with added aprotinin (P = nonsignificant). In contrast, celite ACT and kaolin ACT were greatly prolonged when aprotinin was added to heparinized, noncitrated, and citrated blood (P < 0.05). The aiACT had consistent results at all aprotinin concentrations (P = nonsignificant).


CONCLUSIONS
Aprotinin (160, 320, and 500 KIU/mL) significantly prolongs the ACT value with celite and kaolin activators but not with the aprotinin-insensitive activator.
Dong
Yue
Y
Transfusion, Coagulation and Cardiopulmonary Bypass Research Group, Department of Anesthesiology, Mayo Clinic College of Medicine Rochester, MN 55905, USA.
Nuttall
Gregory A
GA
Oliver
William C
WC
Agarwal
Shvetank
S
Ereth
Mark H
MH
D000328:Adult; D007611:Aprotinin / Q000494:pharmacology*; D001777:Blood Coagulation / Q000187:drug effects*; D002315:Cardiopulmonary Bypass; D007692:Diatomaceous Earth / Q000494:pharmacology; D006801:Humans; D007616:Kaolin / Q000494:pharmacology; D011446:Prospective Studies; D015842:Serine Proteinase Inhibitors / Q000494:pharmacology*; D014914:Whole Blood Coagulation Time
D015842:Serine Proteinase Inhibitors; D007616:Kaolin; D007692:Diatomaceous Earth; D007611:Aprotinin